MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

For the year ending 2025-12-31.

Income Overview

Net Income
-$42,759K
EPS
-$0.32
Unit: Thousand (K) dollars

Income Statement
2025-12-31
Research and development
33,478
General and administrative
15,850
Total operating expenses
49,328
Loss from operations
-49,328
Interest income, net
6,536
Other expense, net
-31
Interest expense
0
Total other income, net
6,505
Loss before income taxes
-42,823
Income tax benefit
-64
Net loss
-42,759
Basic EPS
-0.32
Diluted EPS
-0.32
Basic Average Shares
134,747,198
Diluted Average Shares
134,747,198
Unit: Thousand (K) dollars (except for numbers of shares and EPS).

Time Plot

Show the time plot by selecting a row from the table.

Income Statement

DownloadDownload image
Net loss-$42,759K Income tax benefit-$64K Interest income, net$6,536K Loss before incometaxes-$42,823K Total other income,net$6,505K Other expense, net-$31K Loss from operations-$49,328K Total operatingexpenses$49,328K Research and development$33,478K General andadministrative$15,850K

Trevi Therapeutics, Inc. (TRVI)

Trevi Therapeutics, Inc. (TRVI)